David C Smith
Professor Emeritus of Internal Medicine and Professor Emeritus of Urology
Division of Hematology/Oncology
1500 E. Medical Center Drive
Ann Arbor, Michigan 48109
[email protected]

Available to mentor
David C Smith
Professor Emeritus/a
  • Qualifications
  • Center Memberships
  • Recent Publications
    • Qualifications
    • MD
      University of Washington School of Medicine, Seattle, 1985
    • BS
      Seattle University, Seattle, 1981
    • BA
      Seattle University, Seattle, 1981
    Center Memberships
    • Center Member
      Rogel Cancer Center
    Recent Publications See All Publications
    • Proceeding / Abstract / Poster
      High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine.
      Trump DL, Smith DC, Ellis PG, Rogers MP, Schold SC, Winer EP, Panella TJ, Jordan VC, Fine RL. J Natl Cancer Inst, 1992 Dec 2; 84 (23): 1811 - 1816. DOI:10.1093/jnci/84.23.1811
      PMID: 1359155
    • Journal Article
      Incidental testicular germ cell tumor in a transgender woman: A case report.
      Aslanian RE, Roblee C, Smith DC, Mehra R, Kuzon WM. Urol Case Rep, 2024 Sep; 56: 102817 DOI:10.1016/j.eucr.2024.102817
      PMID: 39280132
    • Journal Article
      Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas.
      Coveler AL, Smith DC, Phillips T, Curti BD, Goel S, Mehta AN, Kuzel TM, Markovic SN, Rixe O, Bajor DL, Gajewski TF, Gutierrez M, Lee HJ, Gopal AK, Caimi P, Heath EI, Thompson JA, Ansari S, Jacquemont C, Topletz-Erickson A, Zhou P, Schmitt MW, Grilley-Olson JE. J Immunother Cancer, 2023 Jun; 11 (6): DOI:10.1136/jitc-2022-005584
      PMID: 37385724
    • Journal Article
      Outpatient administration of paclitaxel, ifosfamide, and cisplatin (TIP) for germ cell tumor.
      Schepers AJ, Smith DC, McDevitt RL. J Oncol Pharm Pract, 2023 Jun; 29 (4): 912 - 916. DOI:10.1177/10781552231165243
      PMID: 36959716
    • Journal Article
      First-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid Tumors.
      Harding JJ, Jungels C, Machiels J-P, Smith DC, Walker C, Ji T, Jiang P, Li X, Asatiani E, Van Cutsem E, Abou-Alfa GK. Target Oncol, 2023 Mar; 18 (2): 181 - 193. DOI:10.1007/s11523-023-00948-8
      PMID: 36787089
    • Journal Article
      Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab.
      Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi FS. J Clin Oncol, 2023 Feb 10; 41 (5): 943 - 954. DOI:10.1200/JCO.22.02272
      PMID: 36750016
    • Journal Article
      A Phase 2 Trial of Nab-paclitaxel in Combination With Anti-PD1 Therapy in Advanced Urothelial Cancer.
      Tsung I, Green E, Palmbos P, Sloan Z, Reichert ZR, Vaishampayan U, Smith DC, Caram MEV, Yentz S, Daignault-Newton S, Hurley L, Nguyen CB, Kraft S, Alva A. J Urol, 2023 Jan; 209 (1): 121 - 130. DOI:10.1097/JU.0000000000002969
      PMID: 36317715
    • Proceeding / Abstract / Poster
      Focal radiation with pulsed systemic therapy of abiraterone, androgen deprivation therapy (ADT), olaparib towards castration-sensitive oligometastatic prostate cancer (FAALCON Trial).
      Reichert ZR, Vaishampayan UN, Caram MV, Alumkal JJ, Alva AS, Palmbos P, Yentz SE, Smith DC, Hearn JWD, Dess RT, Jackson WC. Journal of Clinical Oncology, 2022 Jun 1; 40 (16_suppl): tps5113 - tps5113. DOI:10.1200/jco.2022.40.16_suppl.tps5113